India Active Pharmaceutical Ingredients (API) Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Overview

India Active Pharmaceutical Ingredients (API) Market Snapshot & Metrics Overview

Study Period	2020 - 2032
Forecast Data Period	2027 - 2032
Base Year Market Size (2026)	USD 15.28 Billion
Market Size (2027)	USD 16.46 Billion
Market Size (2032)	USD 23.59 Billion
Growth Rate (2027 - 2032)	7.46 %
Market Concentration	Medium
Major Players* Lupin Aurobindo Pharma Viatris India (Agila) Divi’s Laboratories Ltd Sun Pharmaceuticals Industries	*Disclaimer: Major Players sorted in no particular order

• China
• France
• Germany
• Saudi Arabia
• United Kingdom
• United States

Market Trends and Insights

Government PLI & Bulk-Drug-Park push for self-reliance

Domestic production incentives can translate self-reliance policy into additional sourcing options for Indian formulation manufacturers. Production had commenced for 18 APIs among 41 products approved under the Bulk Drugs PLI scheme by March 2026.^[1] The broader scheme had created 56,800 metric tons per year of capacity for 28 critical key starting materials, drug intermediates and APIs by December 2025. Because precursor and API capacity address different manufacturing steps, this combination can improve the feasibility of domestic production across several routes. The immediate API opportunity therefore rests with covered molecules that have entered production, while upstream capacity can extend localization to additional stages of the manufacturing process.

Accelerated shift of US/EU orders to India post-Biosecure Act

The BIOSECURE Act provisions enacted on December 18, 2025, will restrict specified federal procurement and funding involving designated biotechnology companies after implementation. The prohibitions have not taken effect and start 60 or 90 days after Federal Acquisition Regulation revisions, depending on company category. For affected US customers, qualifying Indian alternatives to potentially covered suppliers in China could create API process-transfer work. European participation would depend on voluntary diversification beyond the law’s US federal scope. ICH guidance normally places prospective API-process validation before downstream drug-product commercial distribution, while allowing specified concurrent-validation exceptions. This sequencing gives Indian CDMOs a potential service opportunity ahead of repeat API sales, even when supplier diversification begins before procurement restrictions take effect.

Scale-up in oncology HPAPI blocks (Visakhapatnam, Hyderabad clusters)

Oncology API expansion can attract development programs when dedicated manufacturing capability is available through a contract partner. During FY2026, Lupin Manufacturing Solutions, Lupin’s CDMO subsidiary, commissioned an oncology-focused manufacturing facility at Visakhapatnam, strengthening its high-potency API capabilities. The subsidiary combines Lupin’s API expertise with a customer-focused contract development and manufacturing model. For an oncology developer, access through this structure can make specialized API production an external manufacturing option within India. For Lupin Manufacturing Solutions, filling the facility depends on winning oncology programs from outside developers, because the subsidiary operates as an independent CDMO platform.

Growth of CRDMO exports serving Phase-I/II innovators

Early-stage API work gives Indian custom manufacturers a route to manufacturing relationships before commercial scale-up. Neuland Laboratories reported 13 active Phase I and 13 active Phase II API projects in Q1 FY27. It also reported 9 active commercial API projects that quarter and scaled complex APIs across 2 Indian manufacturing units during FY2025-26. Management expected development work to generate commercial revenue, although substantial FY27 contributions were uncertain and more molecules could contribute from FY28 onward. This combination makes retention of progressing programs commercially consequential, because a supplier can build production knowledge during development and potentially carry that work into later API manufacturing.

Volatile cost of China-sourced KSMs despite localization

A West Asia conflict-linked pharmaceutical input-cost shock reached India’s API industry in March 2026. An Indian Drug Manufacturers Association committee chair reported that many China-based suppliers, as well as domestic suppliers, had raised raw-material prices. China had supplied about 73.7% by value of India’s imports across 200 categories of APIs, bulk drugs and drug intermediates in FY2024-25. This exposure can complicate fixed-price API contracts when production depends on imported inputs. By September 2026, Lyfius Pharma Pvt. Ltd., an Aurobindo Pharma Ltd subsidiary, had established a fermentation-based Penicillin G KSM facility in Kakinada with installed capacity of 15,000 metric tons annually. Localization can therefore change exposure molecule by molecule, while contracts dependent on other imported intermediates retain the risk of repricing.

Persistent compliance gaps at MSME API units (Schedule M)

For MSME API producers, manufacturing modernization can create a cost of maintaining the business before it creates additional saleable output. In January 2026, India’s API sector cited rising compliance costs under revised Schedule M norms. The sector sought subsidies and soft financing to help MSMEs modernize manufacturing facilities. Compliance modernization can absorb capital without adding output, so the financing request addresses the cost of upgrading the existing manufacturing base. Capacity expansion at smaller suppliers can therefore be delayed if modernization absorbs the capital available for both purposes.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

India Active Pharmaceutical Ingredients (API) Market Segment Analysis

Captive APIs accounted for a 60.94% share of the India active pharmaceutical ingredients (API) market size in 2026. Aurobindo Pharma Ltd reported that 52% of its APIs were captively consumed in FY2024-25. Its API business serves internal needs and external clients, and the company reported 19,000 metric tons of installed API capacity. Aurobindo also linked backward integration and the operational agility of its India-based units to cost efficiencies. An internal formulation base can therefore anchor production planning, while external customers provide another route to commercialize the capabilities of an integrated API manufacturing operation.

Merchant / contract API is forecast to be the fastest-growing segment, with a CAGR of 9.15% over 2027-2032. Laurus Labs Ltd reported that higher CMO-linked API volumes and revenue scale-up from new contracts contributed to stronger utilization in FY2025-26. That creates a growth path through more intensive use of a manufacturing base as contracts bring product programs onto production assets. Higher utilization spreads fixed plant costs over more output, so contract growth can improve economics before producers build additional API capacity.

Synthetic APIs represented a 72.42% India active pharmaceutical ingredients (API) market share in 2026. Themis Medicare had 191 metric tons of annual synthetic API capacity at Vapi and 120 metric tons at its Artemis Biotech division in Hyderabad in Q1 FY27. Separately, Gujarat Themis Biosyn Ltd began commercial production at a multipurpose synthetic and fermentation-based API plant in Vapi, Gujarat, on May 6, 2025.^[2] The plant was established for production of both APIs and intermediates. A multipurpose plant combining synthetic and fermentation-based routes can accommodate several API programs at one site, so capacity need not depend on a single product.

Biotech APIs are forecast to be the fastest-growing segment, at a CAGR of 8.95% over 2027-2032. India-based Concord Biotech describes itself as among the leading global manufacturers of fermentation-based APIs. The company reported 42% year-over-year revenue growth for its company-wide API business in the quarter ended June 30, 2026. Aragen commissioned 2.50 kiloliters of Indian GMP biologics capacity in Q3 FY2026, reported as installed on March 31, 2026, on a platform serving clinical drug-substance and commercial biologics manufacturing. A fermentation specialist’s expanding API business supports an established supply route, while Aragen’s commissioned drug-substance services offer developers access to biologic manufacturing without building their own facilities.

Small-molecule APIs were the largest segment, with 87.4% of the market in 2026. IOL Chemicals and Pharmaceuticals Ltd’s paracetamol Unit 11, with capacity of 10,800 metric tons annually, continued its operational ramp-up during FY2025-26. The company also increased pantoprazole sodium capacity to 276 metric tons annually and clopidogrel bisulfate capacity to 240 metric tons annually. IOL reported healthy demand across paracetamol, metformin, clopidogrel and pantoprazole, alongside strong utilization across major API facilities. IOL’s different line sizes show that small-molecule expansion can be tailored to individual products, even when a manufacturer serves several medicines.

Large-molecule / biologic APIs are forecast to be the fastest-growing segment, with a CAGR of 9.2% over 2027-2032. In May 2026, Aurobindo expected commissioning of TheraNym Unit 1’s 60-kiloliter mammalian cell-culture facility to be completed by end-2026. Its August 2026 schedule placed the start of qualification activities by November 2026 and anchor-product validation batches in 2027. TheraNym was intended to support MSD’s domestic and export supply chains, subject to applicable approvals and customer requirements. Those scheduled validation batches put potential customer supply after equipment commissioning, so biologic API buyers cannot treat the 60-kiloliter installation as immediately available production.

Low/medium-potency APIs were the largest segment, with 85.76% of the market in 2026. Laurus Labs Ltd reported 1,475 kiloliters of non-potent API manufacturing capacity at Unit 6 in Visakhapatnam, Andhra Pradesh, in FY2024-25. A dedicated non-potent API operation gives the producer an established production environment around which to develop its product programs. Additional non-potent programs could therefore use a single established Visakhapatnam operation, reducing the need to replicate site infrastructure.

High-potency APIs are forecast to be the fastest-growing segment, with a CAGR of 8.55% over 2027-2032. Aragen Life Sciences began operating its OneHP platform at Nacharam in Hyderabad in October 2026, with one line designed for 500 to 600 kilograms of API annually. The platform supports highly potent compounds, including cytotoxic molecules and targeted oncology therapies. A line designed around these compounds can give product developers a specialized API manufacturing option within the Hyderabad cluster. A developer whose API requirements fit this line’s scale can seek Indian contract production without establishing its own high-potency manufacturing operation.

Cardiovascular APIs were the largest segment, with 23.12% of the market in 2026. Pharmarack Technologies reported that cardiac medicines were India’s largest finished-medicine therapy segment by sales in July 2026. Cardiac medicines also recorded 3.8% unit growth in July 2026. This downstream activity gives formulators a substantial product base requiring APIs, connecting the segment’s commercial scale to the manufacture of finished cardiovascular medicines. The unit-sales increase points to demand for more finished doses, so cardiovascular API suppliers have a volume-based signal alongside the therapy’s sales ranking.

Oncology is forecast to be the fastest-growing segment, with a CAGR of 8.3% over 2027-2032. In February 2026, Shilpa Medicare reported that expanded capacity for key oncology API molecules had been commissioned. The oncology addition formed part of a broader expansion covering selected API products. Shilpa described the commissioned products as high-demand, so the additional oncology capacity can serve demand for selected molecules without depending on expansion across every therapy.

Pharma and biopharma companies were the largest segment, accounting for 75.75% of the market in 2026. In March 2026, the Department of Pharmaceuticals linked demand for high-dependence APIs to formulation requirements for both domestic consumption and exports. Formulators therefore buy APIs against 2 order streams, domestic consumption and exports. API producers serving this group depend on those formulation plans in both markets, so a shift in either stream can change API requirements.

CDMOs / CMOs are forecast to be the fastest-growing segment, with a CAGR of 8.2% over 2027-2032. In September 2026, Neuland Laboratories announced that its first of 4 scheduled peptide manufacturing modules in Hyderabad had begun operations, adding 7,000 liters of total reactor capacity. It comprised 750 liters for solid-phase peptide synthesis and 6,250 liters for liquid-phase peptide synthesis. The module supports complete peptide API programs and commercial crude-peptide production. This combination can let a contract manufacturer participate at different steps of a peptide production program, widening its commercial role through both complete-API and intermediate manufacturing capabilities.

Geography Analysis

Andhra Pradesh and Telangana combine commercial-scale API operations with facilities focused on niche molecules. Divi’s Laboratories Ltd operates Unit 2, a commercial-scale API manufacturing facility near Visakhapatnam in Andhra Pradesh. SMS Pharmaceuticals, an integrated API and intermediate producer, reported 200 kiloliters of capacity at its Hyderabad manufacturing facility in Telangana in May 2026. Its Bachupally API operation in Telangana was described in March 2025 as serving niche, small-volume and high-value molecules. An API developer can seek commercial-scale supply near Visakhapatnam or niche-molecule manufacturing at Bachupally, so the choice of location follows the production task.

Gujarat’s Jambusar Bulk Drug Park illustrates how the sequencing of civil construction and specialist utilities can shape an API investment. In February 2026, civil works for roads, drainage, water infrastructure, effluent collection and rack systems were at an advanced stage of completion. Gujarat Industrial Development Corporation’s utility projects for effluent treatment, solvent recovery and treatment, storage and disposal facilities were also awarded, with execution underway. Civil works were further along than effluent, solvent-recovery and disposal utilities, so a Jambusar plant could have roads and drainage before the services needed to start manufacturing.

Himachal Pradesh’s Haroli project was being developed around shared infrastructure for bulk-drug units in July 2026. Facilities under implementation included water and power infrastructure, effluent treatment with zero liquid discharge, solvent recovery and warehousing. For a prospective API plant, these common services can reduce the range of utility assets it needs to establish independently. A plant that relies on the park for water, power and effluent treatment cannot start operating until the park operator delivers those services, so its start date follows the park’s implementation schedule.

Regulatory Framework and Outlook

This comparison of selected jurisdictions examines India’s national GMP framework and Telangana’s state approvals from the perspective of an API manufacturer establishing production. National standards and state permissions affect the same project through different obligations, making their commercial effects cumulative. Documented systems form the national manufacturing foundation, while Telangana provides an online licensing route and applies activity-dependent environmental procedures.

India’s Medium rating reflects the requirement to maintain documented systems for inspection, making compliance a recurring operating commitment. Eligible smaller manufacturers’ extension required upgrade-plan applications and ended December 31, 2025, with none subsequently notified, leaving revised Schedule M duties as the baseline for project planning. Telangana’s Medium rating reflects a defined online licensing route combined with activity-dependent environmental approvals. Its 2025 classification transition applies to pending and future consent applications, so the established process requirements provide a basis for continuity in project planning.

Value Chain Stages

The value chain compares intermediate production, API manufacture and analytical testing, focusing on how integrated suppliers and service providers capture value. IOL Chemicals and Pharmaceuticals Ltd describes backward integration across key APIs and intermediates and identifies raw-material cost movements as a business challenge. Integration can therefore change a supplier’s exposure to externally priced inputs, while the API manufacturer’s commercial return also depends on matching production and analytical capacity.

The Department of Pharmaceuticals’ Bulk Drug Parks scheme includes advanced laboratory testing suitable for complex API needs, alongside common industrial infrastructure. External analytical services can complement manufacturers’ internal quality functions, making method development and batch testing a source of capacity flexibility. Method readiness can therefore be planned alongside API ramp-up, reducing the risk that added production capacity is held up by unfinished analytical work.

Key Opportunities for Market Participants

The opportunities compare how policy proposals and developing industrial infrastructure could enable additional API supply to pharmaceutical manufacturers in India. Their commercial value depends on converting support into a workable manufacturing project, with process readiness and capital timing considered together. The initiatives include schemes awaiting approval and a park under development, making approval and implementation material investment conditions.

The central opening is biologic drug-substance supply, where Biopharma SHAKTI would support domestic biologics and biosimilars. On September 18, 2026, Pharmaceutical Secretary Manoj Joshi said the scheme had cleared the Expenditure Finance Committee and awaited Cabinet approval, which he expected within 3 months. Biocon Biologics’ FY2025 drug-substance capabilities included monoclonal antibodies at Biocon Park in Bengaluru. Producers with an established biologic manufacturing base can advance process work before committing support-dependent expansion capital, with approval and final eligibility determining whether policy support enters the investment case.